Related Experiment Video
Updated: Aug 17, 2026
Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder
Published on: April 26, 2024
Decreased prefrontal Myo-inositol in major depressive disorder
Nick J Coupland1, Catherine J Ogilvie, Kathleen M Hegadoren
1Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada. Nick.Coupland@ualberta.ca
Background:
Postmortem studies have shown robust prefrontal cortex glial losses and more subtle neuronal changes in major depressive disorder (MDD). Earlier proton magnetic resonance spectroscopy (1H-MRS) studies of the glial marker myo-inositol in MDD were subject to potential confounds. The primary hypothesis of this study was that MDD patients would show reduced prefrontal/anterior cingulate cortex levels of myo-inositol.
Methods:
Thirteen nonmedicated moderate-severe MDD patients and 13 matched control subjects were studied (six male, seven female per group). Proton magnetic resonance spectroscopy stimulated echo acquisition mode spectra (3.0 T; echo time=168 msec; mixing time=28 msec; repetition time=3000 msec) were obtained from prefrontal/anterior cingulate cortex. Metabolite data were adjusted for tissue composition.
Results:
Patients with MDD showed significantly lower myo-inositol/creatine ratios (.94+/-.23) than control subjects (1.32+/-.37) [F(1,23)=6.9; p=.016].
Conclusions:
These data suggest a reduction of myo-inositol in prefrontal/anterior cingulate cortex in MDD, which could be a consequence of glial loss or altered glial metabolism. Additional in vivo studies of glial markers could add to the understanding of the pathophysiology of MDD.
Insights
Major depressive disorder (MDD) patients show reduced myo-inositol levels in the prefrontal cortex, suggesting potential glial alterations. This finding may offer new insights into the neurobiology of depression.
Area of Science:
- Neuroimaging
- Neuropsychiatry
- Biomarkers
Background:
- Major depressive disorder (MDD) is associated with prefrontal cortex glial changes.
- Previous proton magnetic resonance spectroscopy (1H-MRS) studies on myo-inositol in MDD had potential confounds.
- This study investigated glial marker myo-inositol levels in the prefrontal/anterior cingulate cortex in MDD.
Observation:
- Thirteen nonmedicated MDD patients and 13 controls were studied using 3.0 T 1H-MRS.
- Spectra were acquired from the prefrontal/anterior cingulate cortex.
- Metabolite data were adjusted for tissue composition.
Findings:
- MDD patients exhibited significantly lower myo-inositol/creatine ratios compared to controls.
- The reduction in myo-inositol/creatine ratio was statistically significant (p=.016).
Implications:
- Reduced myo-inositol in the prefrontal/anterior cingulate cortex may indicate glial loss or altered glial metabolism in MDD.
- In vivo studies of glial markers are needed to further understand MDD pathophysiology.
- These findings contribute to the neurobiological understanding of major depressive disorder.
